CytoMed Therapeutics Ltd

CytoMed Therapeutics Ltd

CytoMed Therapeutics Ltd, incorporated in Singapore and publicly listed on the Singapore Exchange (Catalist), advances cell-based immunotherapies for oncology. The company was spun out from the Singapore Institute of Advanced Medicine Holdings, with founding contributions from clinician-scientists and researchers. Public records indicate CytoMed's origins in the early 2020s. The company's therapeutic platform centers on two immune cell types: gamma-delta (γδ) T cells and natural killer (NK) cells. CytoMed aims to produce allogeneic, off-the-shelf cell therapies that target multiple solid tumors, including liver, colorectal, and breast cancers. Preclinical and early clinical data for its lead candidate, CYT-1001, have been published in peer-reviewed journals such as Frontiers in Immunology (per publication, 2023). The company also develops a second platform using modified NK cells, CYT-2001, for hematological malignancies. As a publicly traded firm, CytoMed files periodic reports with the Singapore Exchange, which disclose financial position and operational milestones. The company reported cash and equivalents of approximately SGD 6 million as of the most recent filing (per the firm, 2024). CytoMed maintains a lean team, with fewer than 20 full-time employees per public disclosures. The firm holds patents in several jurisdictions including Singapore, the United States, and Europe. CytoMed's structural differentiator is its focus on allogeneic cell therapies derived from healthy donors, avoiding the cost and complexity of patient-specific CAR-T manufacturing. The company's public listing allows capital access through equity offerings while maintaining research independence. Its partnerships with academic institutions in Singapore provide preclinical validation.